Post-processing of raw MS data was performed using MZmine version 4.9.14, generating a list of high-confidence annotated (Schymanski EL, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. 2014) metabolites detected in more than 90% of samples.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS - negative - reverse-phase","Liquid Chromatography MS - positive - reverse-phase"],"chromatography_protocol":["Chromatographic separation was performed on a Hypersil GOLD C18 column (100 × 2.1 mm, 1.9 µm; Thermo Fisher Scientific) maintained at 40°C. The mobile phase consisted of 0.1% formic acid in Milli-Q water (A) and 0.1% formic acid in acetonitrile (B), delivered at a flow rate of 0.4 mL/min over a total run time of 16 min. The gradient program was as follows: 0% B for 1 min, increased to 100% B over 10 min, maintained at 100% B for 2 min, returned to 0% B in 1 min, and re-equilibrated at 0% B for 2 min.
"],"publication":["Effects of oral ketone ester administration in a pMCAO model (KetoSTROKE study)."],"submitter_name":["Laurent SUISSA"],"submitter_affiliation":["C2VN - Aix-Marseille University"],"organism_part":["brain"],"technology_type":["mass spectrometry assay"],"disease":[""],"extraction_protocol":["Each hemisphere sample was homogenized in methanol and incubated overnight at −20°C.
"],"organism":["Mouse Model"],"full_dataset_link":["https://www.ebi.ac.uk/metabolights/MTBLS14363"],"author":["Laurent SUISSA. Aix-Marseille Université. laurent.suissa@univ-amu.fr.","Emilie DOCHE. Aix-Marseille Université. emilie.doche@ap-hm.fr."],"data_transformation_protocol":["Metabolomic data were log-transformed and normalized using min–max scaling (range 1–2).
"],"study_factor":["Experimental group","Brain hemisphere side"],"submitter_email":["laurent.suissa@univ-amu.fr"],"sample_collection_protocol":["Whole brains were carefully removed ex vivo from euthanized animals, rapidly frozen, and stored at −80°C until LC–MS analysis. At 4°C, brains were dissected into three parts: left hemisphere (ischemic side), right hemisphere.
"],"omics_type":["Metabolomics"],"study_design":["positive ionization polarity","Metabolomics","untargeted analysis","negative ionization polarity","mzmine","Ketosis","brain","Thermo Scientific Dionex Ultimate 3000 HPLC system","sample preparation blank","reference compound mix","Thermo Scientific Q Exactive Plus","experimental sample","Mouse","Ischemic stroke (disorder)","Mouse Model"],"curator_keywords":["positive ionization polarity","Metabolomics","untargeted analysis","negative ionization polarity","mzmine","Ketosis","brain","Thermo Scientific Dionex Ultimate 3000 HPLC system","sample preparation blank","reference compound mix","Thermo Scientific Q Exactive Plus","experimental sample","Mouse","Ischemic stroke (disorder)","Mouse Model"],"mass_spectrometry_protocol":["Each hemisphere sample was homogenized in methanol and incubated overnight at −20°C. Samples were then centrifuged at 13,000 × g for 15 min at 4 °C. Supernatants were dried using a nitrogen evaporator and subsequently reconstituted in 80 µL of a 20:80 acetonitrile/water mixture. Samples were further diluted in 250 µL of a 90:10 Milli-Q water/acetonitrile mixture (LC-MS grade; LiChrosolv, Supelco, Merck, Molsheim, France) containing 0.1% formic acid (Optima LC/MS, Fisher Chemical, Thermo Fisher Scientific). The resulting samples, along with quality control samples (pooled samples and blanks), were analysed using an ESI-Q Exactive Plus mass spectrometer coupled to a Dionex UltiMate 3000 HPLC system (Thermo Fisher Scientific) for chromatographic separation. Full-scan data-dependent MS/MS (ddMS²) acquisition was performed in both positive and negative ionization modes over an m/z range of 80–1000 with a mass resolving power of 35,000 full width at half maximum (FWHM).
"],"metabolite_name":["Myristoylcarnitine","Hexanoylcarnitine","Valerylcarnitine","L-Acetylcarnitine","Arachidonoylcarnitine","Dodecanoylcarnitine","(R)-3-hydroxybutyrylcarnitine","Palmitoylcarnitine","Butyrylcarnitine","1,3-Butanediol","NAD","Hexadecenoylcarnitine","Ketone Ester","Stearoylcarnitine","NADH","Oleoylcarnitine","L-Aspartic acid","Glutamine"],"additional_accession":[]},"is_claimable":false,"name":"Effects of oral ketone ester administration in a pMCAO model (KetoSTROKE study)","description":"Rapid, deep, and sustained systemic ketosis was achieved using an orally administered ketone ester (KE: 3.0 mg/g body weight of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate; DeltaG® Ketone Ester, TΔS® Ltd, Oxfordshire, UK) compared with control (0.9% NaCl) prior to permanent middle cerebral artery occlusion (pMCAO; n=5 mice per group). The severity of cerebral ischemia was assessed in vivo by MRI at 60 minutes after arterial occlusion. To investigate the underlying mechanisms, ex vivo metabolomic analysis of brain tissue was performed. The brain was separated into the ischemic hemisphere and the contralateral control hemisphere.
","dates":{"publication":"2026-04-24","submission":"2026-04-24"},"accession":"MTBLS14363","cross_references":{"HMDB":["HMDB0000005","HMDB0000008","HMDB0000034","HMDB0000045","HMDB0000050","HMDB0000060","HMDB0000061","HMDB0000094","HMDB0000122","HMDB0000133","HMDB0000134","HMDB0000148","HMDB0000156","HMDB0000157","HMDB0000190","HMDB0000195","HMDB0000208","HMDB0000243","HMDB0000251","HMDB0000254","HMDB0000263","HMDB0000277","HMDB0000289","HMDB0000292","HMDB0000807","HMDB0000812","HMDB0000943","HMDB0001058","HMDB0001112","HMDB0001138","HMDB0001264","HMDB0001270","HMDB0001397","HMDB0001401","HMDB0003337","HMDB0006028","HMDB0011681","HMDB0255053","HMDB0000191","HMDB0000201","HMDB0000222","HMDB0000641","HMDB0000756","HMDB0000848","HMDB0000902","HMDB0001487","HMDB0002013","HMDB0002250","HMDB0005065","HMDB0006455","HMDB0013128","HMDB0031320","HMDB0062735","HMDB0253127","HMDB0253792","HMDB0254979"]}}